Cargando…

Combination Therapy in Pulmonary Arterial Hypertension—Targeting the Nitric Oxide and Prostacyclin Pathways

Pulmonary arterial hypertension (PAH) is a chronic and progressive disorder characterized by vascular remodeling of the small pulmonary arteries, resulting in elevated pulmonary vascular resistance and ultimately, right ventricular failure. Expanded understanding of PAH pathophysiology as it pertain...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mandras, Stacy, Kovacs, Gabor, Olschewski, Horst, Broderick, Meredith, Nelsen, Andrew, Shen, Eric, Champion, Hunter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Review Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8261771/ https://www.ncbi.nlm.nih.gov/pubmed/33836637 http://dx.doi.org/10.1177/10742484211006531

Ejemplares similares

Borderline pulmonary pressures in scleroderma - a ‘pre-pulmonary arterial hypertension’ condition?
por: Kovacs, Gabor, et al.
Publicado: (2015)

Clinical and genetic associations with prostacyclin response in pulmonary arterial hypertension
por: Halliday, Stephen J., et al.
Publicado: (2018)

Use of prostacyclin in pulmonary hypertension
por: Vicente, R, et al.
Publicado: (1998)

Role of prostacyclin in pulmonary hypertension
por: Mitchell, Jane A., et al.
Publicado: (2014)

Recent advances in targeting the prostacyclin pathway in pulmonary arterial hypertension
por: Lang, Irene M., et al.
Publicado: (2015)

A prospective, randomized study of inhaled prostacyclin versus nitric oxide in patients with residual pulmonary hypertension after pulmonary endarterectomy
por: Abe, Shinichiro, et al.
Publicado: (2016)

Novel dose–response analyses of treprostinil in pulmonary arterial hypertension and its effects on six-minute walk distance and hospitalizations
por: Ramani, Gautam, et al.
Publicado: (2020)

The definition of pulmonary hypertension: history, practical implications and current controversies
por: Kovacs, Gabor, et al.
Publicado: (2021)

Updated definition of exercise pulmonary hypertension
por: Zeder, Katarina, et al.
Publicado: (2022)

Medication Adherence and Healthcare Costs Among Patients with Pulmonary Arterial Hypertension Treated with Oral Prostacyclins: A Retrospective Cohort Study
por: Dean, Bonnie B., et al.
Publicado: (2020)

Survival and drug persistence in patients receiving inhaled treprostinil at doses greater than 54 µg (nine breaths) four times daily
por: Shapiro, Shelley, et al.
Publicado: (2021)

Subdural hematomas in pulmonary arterial hypertension patients treated with prostacyclin analogs
por: Louis, Lam, et al.
Publicado: (2012)

Management of prostacyclin side effects in adult patients with pulmonary arterial hypertension
por: Kingman, Martha, et al.
Publicado: (2017)

Correction to: Medication Adherence and Healthcare Costs Among Patients with Pulmonary Arterial Hypertension Treated with Oral Prostacyclins: A Retrospective Cohort Study
por: Dean, Bonnie B., et al.
Publicado: (2020)

Nitric oxide and pulmonary arterial hypertension
por: Chester, Adrian H., et al.
Publicado: (2017)

Apelin-17 to diagnose idiopathic pulmonary arterial hypertension: A biomarker study
por: Foris, Vasile, et al.
Publicado: (2023)

Impact of additional selexipag on prostacyclin infusion analogs in patients with pulmonary arterial hypertension
por: Momoi, Mizuki, et al.
Publicado: (2022)

MR 4D flow-based mean pulmonary arterial pressure tracking in pulmonary hypertension
por: Reiter, Ursula, et al.
Publicado: (2020)

Additional Use of Prostacyclin Analogs in Patients With Pulmonary Arterial Hypertension: A Meta-Analysis
por: Wang, Pengwei, et al.
Publicado: (2022)

New Tricks for an Old Drug: Prostacyclins and Right Ventricular Contractility in Pulmonary Arterial Hypertension
por: Wertheim, Bradley M.
Publicado: (2022)

Profile of Endothelin-1, Nitric Oxide, and Prostacyclin Levels in Pulmonary Arterial Hypertension Related to Uncorrected Atrial Septal Defect: Results from a Single Center Study in Indonesia
por: Dinarti, Lucia Kris, et al.
Publicado: (2020)

Comparison of inhaled milrinone, nitric oxide and prostacyclin in acute respiratory distress syndrome
por: Albert, Martin, et al.
Publicado: (2017)

Left atrial acceleration factor as a magnetic resonance 4D flow measure of mean pulmonary artery wedge pressure in pulmonary hypertension
por: Reiter, Gert, et al.
Publicado: (2022)

Prognostic Value of Exercise as Compared to Resting Pulmonary Hypertension in Patients with Normal or Mildly Elevated Pulmonary Arterial Pressure
por: Douschan, Philipp, et al.
Publicado: (2022)

Comparative Efficacy and Safety of Prostacyclin Analogs for Pulmonary Arterial Hypertension: A Network Meta-Analysis
por: Zhang, Huijun, et al.
Publicado: (2016)

Resource utilization at the time of prostacyclin initiation in children in pulmonary arterial hypertension: a multicenter analysis
por: Hart, Stephen A., et al.
Publicado: (2018)

Adverse Events of Prostacyclin Mimetics in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis
por: Picken, Christina, et al.
Publicado: (2019)

Transitions between infused and oral prostacyclin pathway agents in pulmonary arterial hypertension: key considerations
por: Sargent, Therese, et al.
Publicado: (2020)

Are anticoagulants still indicated in pulmonary arterial hypertension?
por: Olschewski, Horst, et al.
Publicado: (2018)

Effect of Photo-Mediated Ultrasound Therapy on Nitric Oxide and Prostacyclin from Endothelial Cells
por: Karthikesh, Madhumithra Subramanian, et al.
Publicado: (2022)

Nitric oxide and pulmonary hypertension
por: Sim, Ji-Yeon
Publicado: (2010)

Therapy for Pulmonary Arterial Hypertension: Glance on Nitric Oxide Pathway
por: Tettey, Abraham, et al.
Publicado: (2021)

Counter-clockwise vortical blood flow in the main pulmonary artery in a patient with patent ductus arteriosus with pulmonary arterial hypertension: a cardiac magnetic resonance imaging case report
por: Reiter, Gert, et al.
Publicado: (2016)

Saudi experience in the management of pulmonary arterial hypertension; the outcome of PAH therapy with the exclusion of chronic parenteral prostacyclin
por: Idrees, Majdy, et al.
Publicado: (2015)

Transition from parental prostacyclin to selexipag: a case series of five pulmonary arterial hypertension patients
por: Holthaus, Nathan, et al.
Publicado: (2019)

First-in-child use of the oral selective prostacyclin IP receptor agonist selexipag in pulmonary arterial hypertension
por: Geerdink, Lianne M., et al.
Publicado: (2017)

Reversal of Right Ventricular Hypertrophy and Dysfunction by Prostacyclin in a Rat Model of Severe Pulmonary Arterial Hypertension
por: Vanderpool, Rebecca R., et al.
Publicado: (2022)

Prognosis of pulmonary arterial hypertension patients with pericardial effusion before and after initiation of parenteral prostacyclin therapy
por: Abu‐Rmaileh, Muhammad, et al.
Publicado: (2023)

Impairment of Anti-Aggregatory Responses to Nitric Oxide and Prostacyclin: Mechanisms and Clinical Implications in Cardiovascular Disease
por: Chirkov, Yuliy Y., et al.
Publicado: (2022)

Quantification of Tortuosity and Fractal Dimension of the Lung Vessels in Pulmonary Hypertension Patients
por: Helmberger, Michael, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_b0iiros6of99hg6j7l1tj35ia9